Chapter 39 — Key Takeaways

The one-paragraph version

The conversation about peptides fails for structural reasons, not personal ones: the patient arrives braced for judgment, the clinician arrives braced for a request they cannot responsibly grant, and both answer questions that were not asked. Fixing it requires three things from you. Disclose everything, for clinical rather than moral reasons — differential diagnosis, interaction checking, peri-operative safety, and monitoring all fail silently on an incomplete history. Ask five questions that work on any medical claim: evidence in someone like me, what would get better, what are the alternatives including nothing, what would you expect and by when, and what would make you stop. And treat it as a repeated game, which means accepting "we don't know," distinguishing a constraint from a refusal, and coming back to report what actually happened — including when nothing did.

The goal

A better conversation, not a won one. Nothing in this chapter is a technique for getting a prescription. A conversation won by maneuvering produces a decision made on bad information, which is the outcome this book exists to prevent.

Why it goes badly (§39.1)

• Both parties arrive braced, and each optimizes against the other's expected behavior
• Appointments are short — a clinician cutting a topic short is usually triaging, not uninterested
• No clinician can know every compound — thousands circulate, most with no literature attached
• "I don't know" is professionally expensive in a system that rewards confidence
• None of this is anyone's fault; misreading a structural pressure as a personality is the most common patient error

Disclosure (§39.2) — the section that matters most for your safety

Tell them. Tell them the truth. Tell them all of it. Four clinical reasons:

Give clinical reasons, not moral ones — the moral framing is what makes people minimize.

The weighing: the risk of an uncomfortable conversation is smaller than the risk of being treated by someone working from an incomplete picture, and it is not close.

What your clinician needs (§39.3)

1. What you are taking — "a compound sold as ___," plus a label photo if you have one
2. How long — start date, continuous or intermittent, anything that changed
3. Why you started — a clinical fact, not a justification
4. What you have noticed — including nothing; "no change at all" is real information
5. What you want — monitor, stop, an evidence opinion, an interaction check, a referral

The asymmetry: you know the marketing claim and not the compound; they know the drug class and not the marketing. Each holds half.

The five questions (§39.4) — the most portable content in the book

• They work on any medical claim in any specialty — a statin, a knee operation, a screening test
• Question 4 converts a hope into a prediction that can fail. Write the answer down with the date
• Question 5 must be asked before starting. Afterward you cannot ask it honestly
• Ask all five regardless of which direction the recommendation points

Bringing evidence (§39.5)

• One study, not a folder. The paper or abstract, not an article about it
• Know its four basics: population, endpoint, comparator, size
• Ask about it, do not present it — and do this because it is true, not because it works better
• An eight-minute appointment cannot absorb a literature review. Book a longer one and say why
• Pharmacists are underused and often have more minutes than a physician

"We don't know" (§39.6)

Three sentences that sound alike:

• "We don't know" — the evidence is absent
• "It doesn't work" — the evidence exists and is negative (a stronger claim; Ch 28's nesiritide)
• "I don't know" — this clinician has not looked into it, which says nothing about the field

Ask which one you are hearing. A clinician who says the evidence is not there is telling you something true and unpopular at a professional cost. That is a better signal than a confident answer built on nothing.

Dismissal (§39.7) and enthusiasm (§39.8)

Dismissal. The diagnostic is whether they engage the claim or the category. A category dismissal is a failure even when the verdict is correct, because it teaches you not to disclose next time. Repair move: "What would change your mind?" — informative in all three of its usual answers. One bad conversation is not a pattern, and do not shop until you find agreement.

Enthusiasm. A recommendation is not a stronger signal than a refusal — both are clinical judgments. Ask the five questions regardless of direction, then ask the structural one: does this practice sell what it recommends? A conflict of interest is a reason to check the evidence, not evidence of dishonesty (Ch 42). "A doctor recommended it" is not evidence about a molecule (Ch 38 §38.10). Discounting a testimonial but not a prescription is half the lesson.

What a clinician cannot do (§39.9)

• Verify an unregulated vial — no chain of custody, no assay (Ch 34)
• Make an unapproved compound safe by supervising it — supervision adds monitoring, interaction checking, and a response pathway, and adds no evidence
• Generate the missing trial
• Tell you what will happen to you individually — only what happened on average to a studied population (Ch 5)
• Escape institutional and licensing constraints. Name this one specifically: otherwise you will read a constraint as a personality. Ask, "is that a policy thing or a clinical judgment thing?"

The repeated game (§39.10)

A clinical relationship compounds, and it compounds on accurate information. A clinician who has known you for years can read your abnormal result against your baseline — often the whole diagnosis.

And the reciprocal move: bring back the outcome. Including when nothing happened. Including when you stopped. Most clinicians never learn how these stories end, because the reports reaching them are filtered toward success by the same mechanism that makes online testimony unreliable (Ch 6). The gray market structurally cannot produce evidence (Ch 19 §19.8) — which makes patient reports, one at a time, the only systematic information ever generated about these compounds.

Ratings issued in this chapter

Dossier move

Field 11 (Verdict) as a conversation. A verdict is a conclusion, and a conclusion invites agreement or disagreement. Convert it into a question, which invites information:

• ❌ → "What would you want to see before considering this?"
• ⚠️ → "Is there a population where this is better established?"
• ✅ for another indication → "Does that apply to my situation?"
• 🔬 → "Is there anything worth watching here, or is it too early?"

And the conversion is a test: a verdict that cannot be turned into an answerable question was probably a feeling.